First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)

This is a Phase II, randomized, multicenter, open-label clinical trial designed to compare Disitamab Vedotin plus Sintilimab and S-1 with Trastuzumab plus chemotherapy ± Sintilimab for first-line treatment of HER2-Positive advanced gastric or gastroesophageal junction adenocarcinoma.

Trial Details

NCT ID
NCT06730373
Phase
PHASE2
Sponsor
Qilu Hospital of Shandong University
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • Disitamab Vedotin
  • Sintilimab
  • S-1
  • Trastuzumab
  • Oxaliplatin
  • Capecitabine
Locations (sample)
  • Zhengzhou, Henan, China|34.75778,113.64861
  • Binzhou, Shandong, China|37.36667,118.01667
  • Dongying, Shandong, China|37.46271,118.49165
  • Jinan, Shandong, China|36.66833,116.99722
  • Jinan, Shandong, China|36.66833,116.99722

Key Eligibility Criteria

  • Aged18-80 years, gender is not limited;
  • Pathologically confirmed locally advanced gastric or gastroesophageal junction adenocarcinoma that is inoperable or has distant metastasis;
  • HER2-Positive (IHC3+or IHC2+/FISH+) ;
  • Has at least 1 measurable lesion as determined by RECIST 1.1;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →